Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Prime Medicine, Inc. (PRME)
NASDAQ:PRME
Prime Medicine, Inc. (PRME) Stock Price & Analysis
127 Followers
PRME Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.11 - $17.20
Previous Close$7.08
Volume759.88K
Average Volume (3M)710.51K
Market Cap
$849.82M
Enterprise Value$821.88M
Total Cash (Recent Filing)$41.57M
Total Debt (Recent Filing)$13.63M
Price to Earnings (P/E)-3.3
Beta2.39
Next Earnings
Aug 05, 2024EPS Estimate
-$0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.13
Shares Outstanding120,030,813
10 Day Avg. Volume734,501
30 Day Avg. Volume710,515
Standard Deviation0.17
R-Squared0.13
Alpha-0.06
Financial Highlights & Ratios
Price to Book (P/B)6.39
Price to Sales (P/S)5379.95
Price to Cash Flow (P/CF)-4.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.89K
Enterprise Value/Gross Profit4.89K
Enterprise Value/Ebitda-5.36
Forecast
1Y Price Target
$15.33Price Target Upside103.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Prime Medicine, Inc. News
Bulls Say, Bears Say
Bulls Say
Regulatory ApprovalFDA approval of PM359 IND is expected, which may significantly increase investor confidence and support the stock's growth prospects.
Strategic PartnershipsThe company's advancement in its pipeline and generation of key preclinical data is attracting favorable partnerships, which could enhance its financial stability and boost its market position.
Technology DifferentiationPrime editing's high specificity and versatility could offer superior and broader applicability than other gene editing approaches, potentially leading to a competitive edge in the market.
Bears Say
Financial StabilityThe company currently only has cash runway through 2024 with limited catalysts over the next months.
Product DevelopmentThe most attractive programs are also the most technically challenging, suggesting that advancement into the clinic could be multiple years away.
Research And DevelopmentThe clinical development path for Prime's 18 pipeline programs remains unclear.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
PRME FAQ
What was Prime Medicine, Inc.’s price range in the past 12 months?
Prime Medicine, Inc. lowest stock price was $4.11 and its highest was $17.20 in the past 12 months.
What is Prime Medicine, Inc.’s market cap?
Currently, no data Available
When is Prime Medicine, Inc.’s upcoming earnings report date?
Prime Medicine, Inc.’s upcoming earnings report date is Aug 05, 2024 which is in 76 days.
How were Prime Medicine, Inc.’s earnings last quarter?
Prime Medicine, Inc. released its earnings results on May 10, 2024. The company reported -$0.44 earnings per share for the quarter, beating the consensus estimate of -$0.455 by $0.015.
Is Prime Medicine, Inc. overvalued?
According to Wall Street analysts Prime Medicine, Inc.’s price is currently Undervalued.
Does Prime Medicine, Inc. pay dividends?
Prime Medicine, Inc. does not currently pay dividends.
What is Prime Medicine, Inc.’s EPS estimate?
Prime Medicine, Inc.’s EPS estimate is -$0.39.
How many shares outstanding does Prime Medicine, Inc. have?
Prime Medicine, Inc. has 120,030,815 shares outstanding.
What happened to Prime Medicine, Inc.’s price movement after its last earnings report?
Prime Medicine, Inc. reported an EPS of -$0.44 in its last earnings report, beating expectations of -$0.455. Following the earnings report the stock price went down -1.923%.
Which hedge fund is a major shareholder of Prime Medicine, Inc.?
Among the largest hedge funds holding Prime Medicine, Inc.’s share is ARK Investment Management LLC. It holds Prime Medicine, Inc.’s shares valued at 42M.
---
Prime Medicine, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.33 (103.59% Upside)
$15.33 (103.59% Upside)
Blogger Sentiment
Bullish
PRME Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 4.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $60.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 10.9%
Last 30 Days ▲ 42.7%
Last 30 Days ▲ 42.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.62%
12-Months-Change
Fundamentals
Return on Equity
-78.27%
Trailing 12-Months
Asset Growth
-1.76%
Trailing 12-Months
Company Description
Prime Medicine, Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs.
---
PRME Stock 12 Month Forecast
Average Price Target
$15.33
▲(103.59% Upside)
Technical Analysis
Best Analysts Covering PRME
1 Year
1 Year Success Rate
3/5 ratings generated profit
1 Year Average Return
+9.12%
reiterated a buy rating 8 days ago
Copying Justin Walsh's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +9.12% per trade.
---